Hualan Biological EngineeringInc (SHE:002007) — Market Cap & Net Worth
Market Cap & Net Worth: Hualan Biological EngineeringInc (002007)
Hualan Biological EngineeringInc (SHE:002007) has a market capitalization of $3.41 Billion (CN¥23.30 Billion) as of September 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #4560 globally and #721 in its home market, demonstrating a -4.35% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hualan Biological EngineeringInc's stock price CN¥12.75 by its total outstanding shares 1827456666 (1.83 Billion). Also see 002007 current and non-current assets for a full breakdown of the balance sheet.
Hualan Biological EngineeringInc Market Cap History: 2015 to 2026
Hualan Biological EngineeringInc's market capitalization history from 2015 to 2026. Data shows growth from $3.42 Billion to $3.41 Billion (0.92% CAGR). Also see 002007 operating cash flow for how efficiently the company converts equity into cash flow.
Index Memberships
Hualan Biological EngineeringInc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Shanghai Shenzhen CSI 300
CSI300
|
$3.94 Trillion | 0.09% | #161 of 285 |
Weight: Hualan Biological EngineeringInc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Hualan Biological EngineeringInc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hualan Biological EngineeringInc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 002007 stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.03x
Hualan Biological EngineeringInc's market cap is 1.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
4.14x
Hualan Biological EngineeringInc's market cap is 4.14 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.42 Billion | $1.47 Billion | $589.12 Million | 2.32x | 5.81x |
| 2016 | $4.48 Billion | $1.93 Billion | $780.31 Million | 2.32x | 5.74x |
| 2017 | $3.41 Billion | $2.37 Billion | $820.82 Million | 1.44x | 4.15x |
| 2018 | $4.20 Billion | $3.22 Billion | $1.14 Billion | 1.30x | 3.68x |
| 2019 | $6.81 Billion | $3.70 Billion | $1.28 Billion | 1.84x | 5.31x |
| 2020 | $10.75 Billion | $5.02 Billion | $1.61 Billion | 2.14x | 6.67x |
| 2021 | $7.48 Billion | $4.44 Billion | $1.30 Billion | 1.69x | 5.76x |
| 2022 | $5.87 Billion | $4.52 Billion | $1.08 Billion | 1.30x | 5.45x |
| 2023 | $5.82 Billion | $5.34 Billion | $1.48 Billion | 1.09x | 3.93x |
| 2024 | $4.51 Billion | $4.38 Billion | $1.09 Billion | 1.03x | 4.14x |
Competitor Companies of 002007 by Market Capitalization
Companies near Hualan Biological EngineeringInc in the global market cap rankings as of September 19, 2026. Review how tangible is Hualan Biological EngineeringInc's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Hualan Biological EngineeringInc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Hualan Biological EngineeringInc Historical Marketcap From 2015 to 2026
Between 2015 and today, Hualan Biological EngineeringInc's market cap moved from $3.42 Billion to $ 3.41 Billion, with a yearly change of 0.92%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥3.41 Billion | -15.73% |
| 2025 | CN¥4.05 Billion | -10.21% |
| 2024 | CN¥4.51 Billion | -22.52% |
| 2023 | CN¥5.82 Billion | -0.87% |
| 2022 | CN¥5.87 Billion | -21.57% |
| 2021 | CN¥7.48 Billion | -30.45% |
| 2020 | CN¥10.75 Billion | +57.89% |
| 2019 | CN¥6.81 Billion | +62.30% |
| 2018 | CN¥4.20 Billion | +23.17% |
| 2017 | CN¥3.41 Billion | -23.98% |
| 2016 | CN¥4.48 Billion | +31.04% |
| 2015 | CN¥3.42 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Hualan Biological EngineeringInc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.41 Billion USD |
| MoneyControl | $3.41 Billion USD |
| MarketWatch | $3.41 Billion USD |
| marketcap.company | $3.41 Billion USD |
| Reuters | $3.41 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hualan Biological EngineeringInc
Hualan Biological Engineering Inc. researches, develops, produces, and commercializes blood products, vaccines, and genetic engineering products in China and internationally. The company offers human serum albumin to treat blood loss trauma, shock caused by burns, intracranial pressure and persistent, liver cirrhosis, and kidney disease; edema for hypoproteinemia, neonatal hyperbilirubinemia, car… Read more